drugset / Trial / NCT06895928
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Timeline
- Start
- 2025-03-28
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-A2102 | Other / unclassified | — | — |
| Background | Adebelimab | Unknown | — | — |
| Background | Ametinib | Small molecule | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Osimertinib | Small molecule | — | — |